Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092877 | 0.80 | — | — | |
| SCHEMBL11922169 | 0.78 | — | — | |
| SCHEMBL16088391 | 0.78 | — | — | |
| SCHEMBL24635124 | 0.78 | LOXL2 (0.41) | LOXL2 | |
| SCHEMBL4593716 | 0.78 | — | — | |
| SCHEMBL824021 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL13527768 | 0.78 | LOXL2 (0.32) | LOXL2 | |
| SCHEMBL22675445 | 0.77 | — | — | |
| SCHEMBL21325538 | 0.75 | NUDT1 (0.36) | — | |
| SCHEMBL24453629 | 0.75 | HTR1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090561-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | LOXL2 1704/4885 |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | LOXL2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.